ENTRY       D11522            Mixture   Drug
NAME        Dolutegravir and lamivudine;
            Dovato (TN)
PRODUCT     DOVATO (ViiV Healthcare Company)
COMPONENT   (Dolutegravir sodium [DR:D10113] | Dolutegravir [DR:D10066]), Lamivudine [DR:D00353]
CLASS       Antiviral
             DG03107  Anti-HIV agent
REMARK      Therapeutic category: 6250
            ATC code: J05AR25
            Product: D11522<JP/US>
EFFICACY    Antiviral
  DISEASE   HIV-1 infection [DS:H01563]
TARGET      HIV-1 reverse transcriptase [KO:K24802]
            HIV-1 integrase [KO:K24803]
  PATHWAY   ko03230(K24802+K24803)  Viral genome structure
            ko03240(K24802+K24803)  Viral replication
            ko03250(K24802+K24803)  Viral life cycle - HIV-1
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AR Antivirals for treatment of HIV infections, combinations
                 J05AR25 Lamivudine and dolutegravir
                  D11522  Dolutegravir and lamivudine &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Combinations
               Dolutegravir/ Lamivudine
                D11522  Dolutegravir and lamivudine
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D11522  Dolutegravir and lamivudine
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               D11522  Dolutegravir and lamivudine
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D11522  Dolutegravir and lamivudine
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV integrase inhibitor
                D11522  Dolutegravir and lamivudine &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11522
DBLINKS     PubChem: 384585498
///
